CannaPharmarx, Inc. Files Q3 2024 10-Q
Ticker: CPMD · Form: 10-Q · Filed: Nov 14, 2024 · CIK: 1081938
| Field | Detail |
|---|---|
| Company | Cannapharmarx, Inc. (CPMD) |
| Form Type | 10-Q |
| Filed Date | Nov 14, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $3.30 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
CannaPharmarx (CPRX) Q3 2024 10-Q filed. Based in Calgary.
AI Summary
CannaPharmarx, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Concord Ventures, Inc., Golden Dragon Holding Co., and CCVG, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its business and mailing address are located in Calgary, Alberta, Canada.
Why It Matters
This filing provides investors with an update on CannaPharmarx, Inc.'s financial performance and operational status for the third quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial information.
Key Numbers
- Q3 2024 — Reporting Period (The period covered by this 10-Q filing.)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations.)
Key Players & Entities
- CannaPharmarx, Inc. (company) — Filer of the 10-Q
- Concord Ventures, Inc. (company) — Former name of CannaPharmarx, Inc.
- Golden Dragon Holding Co. (company) — Former name of CannaPharmarx, Inc.
- CCVG, Inc. (company) — Former name of CannaPharmarx, Inc.
- 20240930 (date) — End of the reporting period
- 20241114 (date) — Filing date
- Calgary (location) — Business and mailing address city
FAQ
What is the primary business of CannaPharmarx, Inc.?
CannaPharmarx, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.
When is the end of the fiscal year for CannaPharmarx, Inc.?
The fiscal year end for CannaPharmarx, Inc. is December 31st.
What were the previous names of CannaPharmarx, Inc.?
CannaPharmarx, Inc. was formerly known as Concord Ventures, Inc., CCVG, Inc., and Golden Dragon Holding Co.
Where are CannaPharmarx, Inc.'s business and mailing addresses located?
The business and mailing addresses for CannaPharmarx, Inc. are in Calgary, Alberta, Canada.
On what date was this 10-Q filing submitted?
This 10-Q filing was submitted on November 14, 2024.
Filing Stats: 4,540 words · 18 min read · ~15 pages · Grade level 18.5 · Accepted 2024-11-13 17:46:21
Key Financial Figures
- $3.30 — ng for optimal product at approximately $3.30 Canadian dollars ("CAD") per gram. This
Filing Documents
- isdr_10q.htm (10-Q) — 1145KB
- isdr_ex311.htm (EX-31.1) — 13KB
- isdr_ex312.htm (EX-31.2) — 10KB
- isdr_ex32.htm (EX-32) — 4KB
- 0001654954-24-014287.txt ( ) — 5214KB
- celz-20240930.xsd (EX-101.SCH) — 57KB
- celz-20240930_lab.xml (EX-101.LAB) — 311KB
- celz-20240930_cal.xml (EX-101.CAL) — 55KB
- celz-20240930_pre.xml (EX-101.PRE) — 270KB
- celz-20240930_def.xml (EX-101.DEF) — 168KB
- isdr_10q_htm.xml (XML) — 760KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION Item 1
Financial Statements (unaudited)
Financial Statements (unaudited) 3 Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation
Management's Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation 21 Item 3
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 28 Item 4
Controls and Procedures
Controls and Procedures 29
OTHER INFORMATION
PART II. OTHER INFORMATION Item 1
Legal Proceedings
Legal Proceedings 29 Item 1A
Risk Factors
Risk Factors 30 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3 Defaults Upon Senior Securities 30 Item 4 Other Information 30 Item 5 Exhibits 30
Signatures
Signatures 31 2 Table of Contents CANNAPHARMAX, INC. CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS September 30, 2024 (Unaudited ) December 31, 2023 ASSETS Current assets Cash $ 6,999 $ 650 Goods and services tax receivable 87,518 61,524 Accounts receivable 183,082 - Inventory 1,219,830 1,133,668 Total current assets 1,497,429 1,195,842 Non-current assets Property, plant and equipment, net 154,043 161,540 Right-of-use building, net 5,511,784 5,870,141 Investments 4,518,127 4,518,127 Total assets $ 11,681,383 $ 11,745,650 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities $ 8,952,717 $ 8,781,169 Accrued interest 1,529,789 523,680 Accrued legal settlement 190,000 190,000 Deferred revenue 278,036 - Notes payable 6,845,740 3,333,925 Convertible notes - net of discount 1,148,114 1,520,858 Derivative conversion feature 651,514 1,264,388 Loans payable - related party 463,642 2,155,484 Liability for right-of-use building, current portion 179,314 190,177 Obligation to issue shares 2,264,286 204,220 Total current liabilities 22,503,152 18,163,901 Non-current liability Liability for right-of-use building 5,762,775 5,734,962 Total liabilities $ 28,265,927 $ 23,898,863 STOCKHOLDERS' DEFICIT Preferred stock series A, $ 1.00 par value, 100,000 shares authorized, 74,416 and 84,416 issued and outstanding as at September 30, 2024 and December 31, 2023, respectively $ 74,416 $ 84,416 Preferred stock series B, $ 1.00 par value, 3,000,000 shares authorized, 455,000 and 2,455,000 shares issued and outstanding as at September 30, 2024 and December 31, 2023, respectively 455,000 2,455,000 Preferred stock series C, $ 1.00 par value, 100,000 shares authorized, 100,000 shares issued and outstanding as at September 30, 2024 and December 31, 2023 100,000 750,000 Common stock, $ 0.0001 par